Chinyere E Okpara
Overview
Explore the profile of Chinyere E Okpara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
200
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Matsubara N, de Wit R, Balar A, Siefker-Radtke A, Zolnierek J, Csoszi T, et al.
Eur Urol
. 2023 Oct;
85(3):229-238.
PMID: 37778952
Background: Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable safety in patients with platinum-refractory urothelial carcinoma (UC). Objective: To evaluate pembrolizumab plus either lenvatinib or placebo as first-line therapy...
12.
Grunwald V, Powles T, Eto M, Kopyltsov E, Rha S, Porta C, et al.
Front Oncol
. 2023 Sep;
13:1223282.
PMID: 37664025
Introduction: The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including...
13.
Colombo N, Lorusso D, Monk B, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, et al.
Oncologist
. 2023 Jul;
29(1):25-35.
PMID: 37523661
Background: Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endometrial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression following...
14.
Pearson A, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor E, Copland C, et al.
Eur J Cancer
. 2022 Jul;
173:71-90.
PMID: 35863108
The eighth Paediatric Strategy Forum focused on multi-targeted kinase inhibitors (mTKIs) in osteosarcoma and Ewing sarcoma. The development of curative, innovative products in these tumours is a high priority and...
15.
Motzer R, Taylor M, Evans T, Okusaka T, Glen H, Lubiniecki G, et al.
Expert Rev Anticancer Ther
. 2022 Mar;
22(4):383-400.
PMID: 35260027
Introduction: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across multiple cancer types. The recommended starting doses for lenvatinib differ across cancer types...
16.
Gaspar N, Venkatramani R, Hecker-Nolting S, Gallego Melcon S, Locatelli F, Bautista F, et al.
Lancet Oncol
. 2021 Aug;
22(9):1312-1321.
PMID: 34416158
Background: Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib...
17.
Gaspar N, Campbell-Hewson Q, Huang J, Okpara C, Bautista F
Future Oncol
. 2021 Aug;
17(32):4249-4261.
PMID: 34382412
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in...
18.
Lee C, Shah A, Rasco D, Rao A, Taylor M, Di Simone C, et al.
Lancet Oncol
. 2021 Jun;
22(7):946-958.
PMID: 34143969
Background: Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune...
19.
Alghamdi A, Munday J, Campagnaro G, Gurvic D, Svensson F, Okpara C, et al.
Elife
. 2020 Aug;
9.
PMID: 32762841
Mutations in the aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common...